The FDA has issued a safety warning about the use of Ocaliva in patients with primary biliary cholangitis, specifically those who do not have cirrhosis of the liver.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
FDA highlights injury risk for some patients on liver disease drug
